GlaxoSmithKline is making headway in the fiercely competitive Chinese vaccine market after winning regulatory approval there for one of its cancer vaccines

Cervarix is designed to fight two types of human papillomavirus.

The Brentford based pharmaceutical giant is the first foreign producer of a jab to be approved by Chinese regulators.